Outcomes Capture & Utilization
For Patients Everywhere
The use of the Perthera Precision Oncology Platform has achieved significant results in a number of cancer types. Nearly 50% of the resected cancer patients analyzed by the Perthera Precision Oncology Platform to date have had “actionable mutations”, meaning that 1 in 2 patients analyzed had tumors with mutations that could be treated with targeted molecular therapies.
In numerous clinical publications, Perthera has published results that demonstrate that patients with actionable mutations who were treated with a highly ranked treatment option listed in their Perthera Analysis had significantly higher Progression-Free Survival (PFS) and Overall Survival (OS) rates. These results have been featured at oncology conferences such as ASCO Annual, and in journals such as The Lancet Oncology, AACR, etc.